Raymond James Has Bearish Estimate for TSE:MDP Q3 Earnings

Medexus Pharmaceuticals Inc. (TSE:MDP) – Research analysts at Raymond James reduced their Q3 2026 earnings per share estimates for shares of Medexus Pharmaceuticals in a report issued on Tuesday, January 7th. Raymond James analyst M. Freeman now forecasts that the company will earn $0.22 per share for the quarter, down from their prior forecast of $0.24. Raymond James currently has a “Strong-Buy” rating and a $4.00 target price on the stock. The consensus estimate for Medexus Pharmaceuticals’ current full-year earnings is $0.16 per share. Raymond James also issued estimates for Medexus Pharmaceuticals’ Q4 2026 earnings at $0.23 EPS, FY2026 earnings at $0.89 EPS, FY2027 earnings at $0.88 EPS, FY2028 earnings at $0.80 EPS and FY2029 earnings at $0.77 EPS.

MDP has been the subject of several other reports. Alliance Global Partners upgraded Medexus Pharmaceuticals to a “strong-buy” rating in a research report on Monday, December 23rd. Leede Financial set a C$8.25 price objective on shares of Medexus Pharmaceuticals and gave the stock a “speculative buy” rating in a research report on Monday, September 30th. Two equities research analysts have rated the stock with a buy rating and four have given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Strong Buy” and a consensus target price of C$5.25.

Medexus Pharmaceuticals Trading Up 13.1 %

Shares of Medexus Pharmaceuticals stock opened at C$4.07 on Thursday. Medexus Pharmaceuticals has a 12 month low of C$1.47 and a 12 month high of C$4.07. The company has a market capitalization of C$99.84 million, a PE ratio of 81.40 and a beta of 1.96. The stock’s fifty day simple moving average is C$2.74 and its 200 day simple moving average is C$2.52.

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.